International perspectives on newborn screening

Journal of Inherited Metabolic Disease

Volumn 29, Issue 2-3, 2006, Pages 390-396

  Pollitt, Rodney J ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; GLUCOSE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE;

AMINO ACID ANALYSIS; ARTICLE; BIOTINIDASE DEFICIENCY; BLOOD SAMPLING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; ENZYME DEFICIENCY; EUROPE; EVIDENCE BASED MEDICINE; FOLLOW UP; GALACTOSEMIA; GERMANY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; HOMOCYSTINURIA; HUMAN; HYPERPHENYLALANINEMIA; HYPOPLASIA; HYPOTHYROIDISM; MEDICAL RESEARCH; MEDICAL SPECIALIST; METHYLMALONIC ACIDURIA; NATIONAL HEALTH SERVICE; NEWBORN; NEWBORN MORBIDITY; NEWBORN MORTALITY; NEWBORN SCREENING; PHENYLKETONURIA; PUBLIC HEALTH; QUESTIONNAIRE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SOCIAL SECURITY; STAFF TRAINING; STATISTICAL SIGNIFICANCE; UMBILICAL CORD BLOOD; UNITED KINGDOM; UNITED STATES;

GERMANY; GREAT BRITAIN; HEALTH POLICY; HUMANS; INFANT, NEWBORN; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; PROGRAM EVALUATION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; UNITED STATES; WORLD HEALTH;

EID: 33745095968     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-006-0259-2     Document Type: Article

References (19)

1. Autti-Rämö I, MäkElä M, Sintonen H, et al (2005) Expanding screening for rare metabolic disease in the newborn: An analysis of costs, effect and ethical consequences of decision-making in Finland. Acta Paediatr 94: 1126-1136.
2. Dionisi-Vici C, Deodato F, Röschinger W, Rhead W, Wilcken B (2006) 'Classical' organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: Long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis 29: 383-389.
3. Green A, Pollitt RJ (1999) Population newborn screening for inherited metabolic disease: Current UK perspectives. J Inherit Metab Dis 22: 572-579.
4. Hall DM, Davis A (2000) Commentary on Kennedy CR, Neonatal screening for hearing impairment. Arch Dis Child 83: 382-383.
5. Hall DM, Michel JM (1995) Screening in infancy. Arch Dis Child 72: 93-96.
6. Lilford RJ, Thornton JG, Braunholtz D (1995) Clinical trials and rare diseases: A way out of the conundrum. Br Med J 311: 1621-1625.
7. National Research Council. Committee for the Study of Inborn Errors of Metabolism (1975) Genetic Screening: Programs, Principles, and Research. Washington DC: National Academy of Sciences.
8. Nennstiel-Ratzel U, Arenz S, Maier EM, et al (2005) Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A>G identified by neonatal screening. Mol Genet Metab 85: 157-159.
9. Oerton J, Downing M, Andresen BS, et al (2005) Predictive value, clinical status and genotype of medium-chain acyl CoA dehydrogenase deficiency (MCADD) ascertained by screening at one week of age using electrospray tandem mass spectrometry of underivatized blood spots: findings from a UK multicentre trial [abstract]. J Inherit Metab Dis 28(Supplement 1):9.
10. Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S (2004) Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review. Health Technol Assessment 8(12):1-121 (plus 47 appendices).
11. Parsons EP, Clarke AJ, Hood K, Lycett E, Bradley DM (2002) Newborn screening for Duchenne muscular dystrophy: A psychosocial study. Arch Dis Child Fetal Neonatal Ed 86: F91-95.
12. Pollitt RJ (1999) Principles and performance: Assessing the evidence. Acta Paediatr 88(Supplement 432):40-44.
13. Pollitt RJ (2001) Newborn mass screening versus selective investigation: benefits and costs. J Inherit Metab Dis 24: 229-302.
14. Pollitt RJ, Green A, McCabe CJ, et al (1997) Neonatal screening for inborn errors of metabolism: Cost, yield and outcome. Health Technol Assessment 1(7):1-203.
15. Sander J, Sander S, Steuerwald U, et al (2005) Neonatal screening for defects of the mitochondrial trifunctional protein. Mol Genet Metab 85: 108-114.
16. Seymour CA, Thomason, MJ Chalmers RA, et al (1997) Newborn screening for inborn errors of metabolism: A systematic review. Health Technol Assessment 1(11):1-95.
17. Schulze A, Lindner M, Kohlmüller D, OlgemölLer K, Mayatepek E, Hoffmann GF (2003) Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: Results, outcome, and implications. Pediatrics 111: 1399-1406.
18. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR (2000) Analysis of screening for maple syrup urine disease: Modelling using evidence from multiple studies. In: Baysian Methods in Health Technology Assessment: A Review. Health Technol Assessment 4(38):72-74.
19. Wilson JMG, Jungner G (1968) Principles of Screening for Disease. Geneva: World Health Organization, 1968.